Eating Disorders and GLP-1 RAs

PDF Available ?

Yes

Year

2025

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications
originally developed to treat type 2 diabetes. GLP-1 RAs are now being used as an approved or off-label treatment for weight loss and have been trialled as a treatment for some eating disorders such as binge eating disorder (BED).

There is limited research available to help researchers, clinicians and patients/consumers to understand 
the relationships between GLP-1 RAs and eating disorders. However, it is thought that GLP-1 RAs may 
negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information about GLP-1 RAs as well as their possible interaction with eating disorders including physical and psychological impacts. Practice points are provided for clinicians.

« Back to Browse Resources

See also

Stepped System of Care - Filipino

Pinagsama ng National Eating Distorders Collaboration (NEDC) ang dalawang dekada ng sektor at consensus ng karanasan at pag-unlad ng serbisyo upang maging modelo ng yugto-yugtong sistema ng pangangalaga para sa mga sakit sa gawi sa pagkain (eating disorders) (Bilang 1).

Read more

Eating Disorders and GLP-1 RAs

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes.

Read more

RESET - A Conversation About Boys' Body Image

Australia's first digital body image program for boys, RESET is a digital education program designed to start a deeper conversation with boys about negative body image and eating disorders.

Read more

Mind, Body & Fertility: The Connection Between Fertility Care, Disordered Eating and Eating Disorders

People seeking fertility care are significantly more likely than the general population to have an experience of body image issues, disordered eating or an eating disorder.

Read more